Market Performance of Abcellera Biologics
Abcellera Biologics (ticker: ABCL) advanced by 1.1 % during the 24‑hour trading window that closed at 07:37 AM Central Europe on Wednesday, 21 March 2026. At the moment of writing, one share of the Canadian‑based biopharmaceutical company trades at USD 11.71 on major exchanges. The publicly available supply stands at 323.7 million shares, and the firm’s market capitalization is USD 3.8 billion.
Trading Activity
- Turnover: In the preceding 24 hours, roughly USD 37.3 million of Abcellera shares changed hands.
- Month‑to‑date trend: Over the last month, the stock has experienced a decline of 5.77 %.
- Moving average: The simple moving average over the past 200 trading days is USD 6.48.
- 52‑week range: The share price’s all‑time high over the last 52 weeks was USD 15.02 (recorded on 30 September 2026), while the low was USD 2.74 (recorded on 5 February 2026).
These figures provide context for the current market sentiment: despite a modest intraday gain, the stock remains under pressure relative to its recent performance and long‑term trend.
Comparison with Peer Companies
The following table summarizes the 24‑hour performance of several Canadian peer firms within the energy, real‑estate, and utilities sectors, offering a benchmark for Abcellera’s relative movement:
| Company | 24‑hour change | Current price | Market cap | P/E ratio |
|---|---|---|---|---|
| Gibson Energy (GEI.TO) | 0 % | CAD 33.25 | CAD 5.7 bn | 33.07 |
| Skeena (SKE.TO) | –0.22 % | CAD 44.12 | CAD 5.6 bn | – |
| Exchange Income (EIF.TO) | –2.08 % | CAD 113.03 | CAD 6.5 bn | 32.03 |
| Colliers Gr (CIGI.TO) | –1.37 % | CAD 130.79 | CAD 6.4 bn | 42.22 |
| Algonquin Power & Utilities (AQN.TO) | –2.02 % | CAD 7.35 | CAD 5.6 bn | 21.54 |
While most of these peers registered declines, Abcellera’s slight uptick suggests a relative resilience, possibly reflecting investor confidence in its drug discovery pipeline.
Company Overview
Abcellera Biologics Inc., headquartered in Vancouver, Canada, operates in the healthcare sector with a focus on next‑generation therapeutic antibodies. The company harnesses a suite of proprietary technologies—including immunizations, microfluidics, high‑throughput imaging, genomics, computation, and laboratory automation—to accelerate drug discovery. Abcellera’s mission is to deliver cutting‑edge therapies to patients in Canada and beyond. Further details about its product portfolio and scientific initiatives can be found on its website at www.abcellera.com .
